Lisocabtagene maraleucel (Breyanzi), a personalized cell-based gene therapy, has been approved to treat adults with various relapsed or refractory large B-cell lymphomas.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.NAJ.0000753644.07326.f6 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.